Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

AXIS DIAGNOSTICS, INC.

NPI: 1730599416 · SAN ANTONIO, TX 78232 · Clinical Medical Laboratory · NPI assigned 05/02/2014

$435K
Total Medicaid Paid
42,851
Total Claims
26,111
Beneficiaries
46
Codes Billed
2018-01
First Month
2018-08
Last Month

Provider Details

Authorized OfficialWHITE, WILLIAM (CEO)
NPI Enumeration Date05/02/2014

Related Entities

Other providers sharing the same authorized official: WHITE, WILLIAM

ProviderCityStateTotal Paid
ADVOGENEX INC CRANSTON RI $14K
ORION OAKS DENTAL LAKE ORION MI $984.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 42,851 $435K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 5,861 2,208 $175K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 7,474 3,156 $154K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 688 381 $24K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1,121 882 $19K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 564 439 $5K
80372 1,007 695 $4K
80323 648 466 $3K
80373 951 665 $3K
80367 1,007 695 $3K
80336 782 556 $3K
80370 848 599 $2K
80356 933 660 $2K
80368 842 588 $2K
80354 1,007 695 $2K
80338 744 515 $2K
80355 807 556 $2K
80364 947 662 $2K
80329 686 493 $2K
80366 778 532 $2K
80342 754 520 $2K
80334 708 493 $2K
80348 1,023 701 $2K
80358 950 664 $2K
80346 964 672 $2K
80339 717 498 $2K
80357 627 454 $2K
80375 604 437 $2K
80350 671 489 $1K
80325 898 631 $1K
80353 928 662 $1K
80360 984 682 $1K
80345 774 557 $1K
80359 925 654 $860.31
80349 899 620 $810.52
83992 927 656 $794.90
80371 645 463 $616.53
80362 990 686 $406.97
80321 17 13 $112.88
80340 18 14 $95.58
80344 18 14 $95.58
80332 18 14 $95.58
83986 15 12 $0.00
80324 25 20 $0.00
80365 20 15 $0.00
82570 15 12 $0.00
80361 22 15 $0.00